Published in EMBO Mol Med on October 04, 2016
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Oncotarget (2016) 0.75
Pharmacological and immunological targeting of tumor mesenchymalization. Pharmacol Ther (2016) 0.75
Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator. Oncol Lett (2017) 0.75
Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Oncogene (2017) 0.75
Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells. Cancer Sci (2017) 0.75
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Identification of cells initiating human melanomas. Nature (2008) 8.28
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol (2014) 2.40
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell (2015) 1.94
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell (2015) 1.91
Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell (2007) 1.71
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med (2014) 1.51
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun (2014) 1.48
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol (2014) 1.35
ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle (2015) 1.30
Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev (2013) 1.25
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 1.16
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene (2014) 1.15
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun (2015) 1.10
Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ (2014) 1.05
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene (2011) 1.05
Slug expression during melanoma progression. Am J Pathol (2012) 0.97
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med (2015) 0.93
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One (2014) 0.92
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene (2014) 0.91
CD271 is an imperfect marker for melanoma initiating cells. Oncotarget (2014) 0.86
Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs. Cell Biol Int (2014) 0.85
Plasticity of melanoma and EMT-TF reprogramming. Oncotarget (2014) 0.82
Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat Commun (2014) 0.81